Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adsorbed acellular diphtheria-pertussis-tetanus + Haemophilus influenzae type b combination vaccine
- Development stage
- Unknown
- Lead developer
- Yunnan Provincial Center for Disease Control and Prevention
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The adsorbed acellular diphtheria-pertussis-tetanus + Haemophilus influenzae type b combination vaccine (DTaP/Hib) is an investigational biologic being developed by the Yunnan Provincial Center for Disease Control and Prevention in China. This combination vaccine is designed to provide active immunization against four major pediatric diseases: pertussis (whooping cough), diphtheria, tetanus, and Haemophilus influenzae type b (Hib) infection. The formulation consists of acellular pertussis antigens (including pertussis toxoid and filamentous hemagglutinin), diphtheria toxoid, and tetanus toxoid, all adsorbed onto an aluminum adjuvant, combined with a Hib conjugate component (polyribosyl-ribitol-phosphate, PRP). It is currently being evaluated in a Phase I clinical trial in China to assess safety and preliminary immunogenicity in healthy participants, including infants as young as 3 months old.
- Other names
- adsorbed acellular diphtheria-pertussis-tetanus + Haemophilus influenzae type b combination vaccineDTaP/Hibadsorbed acellular DPT/Hib combination vaccine
02
Targets
γδ TCR (T-cell receptor)Diphtheria toxinBCR (Immunoglobulin G B Cell Receptor)
Beyond the preview
Go deeper on adsorbed acellular diphtheria-pertussis-tetanus + Haemophilus influenzae type b combination vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adsorbed acellular diphtheria-pertussis-tetanus + Haemophilus influenzae type b combination vaccine.